Immunity, Mucosal

• 

  Subject Areas on Research

  • A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects. 
  • A comparison of non-toxin vaccine adjuvants for their ability to enhance the immunogenicity of nasally-administered anthrax recombinant protective antigen. 
  • Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. 
  • Alphavirus replicon particles acting as adjuvants promote CD8+ T cell responses to co-delivered antigen. 
  • Association of HIV-1 Envelope-Specific Breast Milk IgA Responses with Reduced Risk of Postnatal Mother-to-Child Transmission of HIV-1. 
  • Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies. 
  • CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge. 
  • Chemokine-adjuvanted electroporated DNA vaccine induces substantial protection from simian immunodeficiency virus vaginal challenge. 
  • Combined HIV-1 Envelope Systemic and Mucosal Immunization of Lactating Rhesus Monkeys Induces a Robust Immunoglobulin A Isotype B Cell Response in Breast Milk. 
  • Combined systemic and mucosal immunization with microsphere-encapsulated inactivated simian immunodeficiency virus elicits serum, vaginal, and tracheal antibody responses in female rhesus macaques. 
  • Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector. 
  • Comparison of systemic and mucosal immunization with helper-dependent adenoviruses for vaccination against mucosal challenge with SHIV. 
  • Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses. 
  • Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. 
  • Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. 
  • Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates. 
  • Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. 
  • Critical issues in mucosal immunity for HIV-1 vaccine development. 
  • Cytokine requirements for induction of systemic and mucosal CTL after nasal immunization. 
  • Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization. 
  • DNA-MVA vaccine protection after X4 SHIV challenge in macaques correlates with day-of-challenge antiviral CD4+ cell-mediated immunity levels and postchallenge preservation of CD4+ T cell memory. 
  • DNA-MVA-protein vaccination of rhesus macaques induces HIV-specific immunity in mucosal-associated lymph nodes and functional antibodies. 
  • Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity. 
  • Dry powder vaccines for mucosal administration: critical factors in manufacture and delivery. 
  • Effect of bismuth salts on systemic and mucosal immune responses to orally administered cholera toxin. 
  • Effective induction of simian immunodeficiency virus-specific systemic and mucosal immune responses in primates by vaccination with proviral DNA producing intact but noninfectious virions. 
  • Efficient lymphocyte migration across high endothelial venules of mouse Peyer's patches requires overlapping expression of L-selectin and beta7 integrin. 
  • Elite Control, Gut CD4 T Cell Sparing, and Enhanced Mucosal T Cell Responses in Macaca nemestrina Infected by a Simian Immunodeficiency Virus Lacking a gp41 Trafficking Motif. 
  • Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. 
  • Evaluation of humoral, mucosal, and cellular immune responses following co-immunization of HIV-1 Gag and Env proteins expressed by Newcastle disease virus. 
  • Extraintestinal dissemination of Salmonella by CD18-expressing phagocytes. 
  • Generation of mucosal anti-human immunodeficiency virus type 1 T-cell responses by recombinant Mycobacterium smegmatis. 
  • HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life. 
  • HIV-1 specific IgA detected in vaginal secretions of HIV uninfected women participating in a microbicide trial in Southern Africa are primarily directed toward gp120 and gp140 specificities. 
  • HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge. 
  • Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel combinatorial approaches for enhancing responses. 
  • Immune mechanisms responsible for vaccination against and clearance of mucosal and lymphatic norovirus infection. 
  • Immunization with Haemophilus influenzae Hap adhesin protects against nasopharyngeal colonization in experimental mice. 
  • Immunoregulation on the ocular surface: 2nd Cullen Symposium. 
  • Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen. 
  • Improving defences at the portal of HIV entry: mucosal and innate immunity. 
  • Induction of mucosal antibody responses by microsphere-encapsulated formalin-inactivated simian immunodeficiency virus in a male urethral challenge model. 
  • Limited contribution of mucosal IgA to Simian immunodeficiency virus (SIV)-specific neutralizing antibody response and virus envelope evolution in breast milk of SIV-infected, lactating rhesus monkeys. 
  • Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeys. 
  • Maximal adjuvant activity of nasally delivered IL-1α requires adjuvant-responsive CD11c(+) cells and does not correlate with adjuvant-induced in vivo cytokine production. 
  • Modified Newcastle Disease virus as an improved vaccine vector against Simian Immunodeficiency virus. 
  • Mucosal B Cells Are Associated with Delayed SIV Acquisition in Vaccinated Female but Not Male Rhesus Macaques Following SIVmac251 Rectal Challenge. 
  • Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. 
  • Mucosal and systemic adjuvant activity of alphavirus replicon particles. 
  • Mucosal and systemic immune activation is present in human immunodeficiency virus-exposed seronegative women. 
  • Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A). 
  • Mucosal vaccine development for botulinum intoxication. 
  • Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3. 
  • Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239. 
  • Nasal DNA-MVA SIV vaccination provides more significant protection from progression to AIDS than a similar intramuscular vaccination. 
  • Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection. 
  • Neutrophil CD11b, L-selectin and Fc IgA receptors in patients with dermatitis herpetiformis. 
  • Non-replicating mucosal and systemic vaccines: quantitative and qualitative differences in the Ag-specific CD8(+) T cell population in different tissues. 
  • Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination. 
  • Novel intranasal pertussis vaccine based on bacterium-like particles as a mucosal adjuvant. 
  • Oral immunogenicity of the plant proteinase bromelain. 
  • Oropharyngeal Candida colonization and human immunodeficiency virus type 1 infection. 
  • Pathophysiology of dermatitis herpetiformis: a model for cutaneous manifestations of gastrointestinal inflammation. 
  • Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. 
  • Postnatal pre- and postexposure passive immunization strategies: protection of neonatal macaques against oral simian-human immunodeficiency virus challenge. 
  • Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges. 
  • Protection of macaques against intrarectal infection by a combination immunization regimen with recombinant simian immunodeficiency virus SIVmne gp160 vaccines. 
  • Rapid SIV Env-specific mucosal and serum antibody induction augments cellular immunity in protecting immunized, elite-controller macaques against high dose heterologous SIV challenge. 
  • Regulation of mucosal and systemic antibody responses by T helper cell subsets, macrophages, and derived cytokines following oral immunization with live recombinant Salmonella. 
  • Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac251) challenge. 
  • Resistance to infection, early and persistent suppression of simian immunodeficiency virus SIVmac251 viremia, and significant reduction of tissue viral burden after mucosal vaccination in female rhesus macaques. 
  • Single epitope mucosal vaccine delivered via immuno-stimulating complexes induces low level of immunity against simian-HIV. 
  • Th2 cells: orchestrating barrier immunity. 
  • The contribution of type I interferon signaling to immunity induced by alphavirus replicon vaccines. 
  • The impact of pregnancy on anti-HIV activity of cervicovaginal secretions. 
  • Tissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaques. 
  • Tracking salmonella-specific CD4 T cells in vivo reveals a local mucosal response to a disseminated infection. 
  • Vaccination with Vaxfectin(®) adjuvanted SIV DNA induces long-lasting humoral immune responses able to reduce SIVmac251 Viremia. 
  • Viral vectored granulocyte-macrophage colony stimulating factor inhibits vaccine protection in an SIV challenge model: protection correlates with neutralizing antibody. 
  • gammadelta cells and the regulation of mucosal immune responses. 
  • α4β7 Integrin is essential for contact hypersensitivity by regulating migration of T cells to skin. 
• 

  Keywords of People

  • Ferrari, Guido, Associate Professor of Surgery, Molecular Genetics and Microbiology
  • Weinhold, Kent James, Joseph W. and Dorothy W. Beard Professor of Experimental Surgery, in the School of Medicine, Immunology